-
Mashup Score: 3The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial - 3 day(s) ago
Nature Medicine – In a phase 2 trial, the oral type II RAF inhibitor tovorafenib exhibited an overall response rate of 67% in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab - 11 day(s) ago
Nature Reviews Clinical Oncology – Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of patients with EGFR-mutated non-small-cell…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers - 13 day(s) ago
Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3AIās Threat to the Medical Profession - 13 day(s) ago
This Viewpoint discusses the potential drawbacks of the use of artificial intelligence (AI) in medicine, for example, the loss of certain skills due to the reliance on AI, and how physicians should consider how to take advantage of the potential benefits of AI without losing control over their…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7What Clinicians Need to Know About TikTok - 13 day(s) ago
This Medical News article discusses research on health information being shared on the social media platform.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Summary:. Revolutionary advancements in oncology have transformed lives, but the clinical trials ecosystem encounters challenges, including restricted access to innovative therapies and a lack of diversity in participant representation. A vision emerges for democratized, globally accessible oncology trials, necessitating collaboration among researchers, clinicians, patients, and policymakers to shift from converting complex, exclusive trials into a dynamic, inclusive force against cancer.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Summary:. Revolutionary advancements in oncology have transformed lives, but the clinical trials ecosystem encounters challenges, including restricted access to innovative therapies and a lack of diversity in participant representation. A vision emerges for democratized, globally accessible oncology trials, necessitating collaboration among researchers, clinicians, patients, and policymakers to shift from converting complex, exclusive trials into a dynamic, inclusive force against cancer.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
A Baylor study demonstrating the power of sewage as an early-warning system for viral disease outbreaks won the 2024 STAT Madness popular vote.
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access - 20 day(s) ago
This clinical care review summarizes government policies for the safe conduct of clinical trials using the telehealth and decentralized clinical trials digital health models.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - 20 day(s) ago
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Hem/OncsTweet
Link to @NatureMedicine paper šš¼The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial @SaheliSadanand https://t.co/N1u8GKFCEt